# Compass Pathways
Who / What
Compass Pathways is a British pharmaceutical company specializing in the development of psychedelic medicines as potential therapeutic treatments. Its primary focus lies in advancing research and clinical trials for compounds like psilocybin, which has shown promise in addressing conditions such as treatment-resistant depression.
---
Background & History
Founded within the context of emerging interest in psychedelics as medical tools, Compass Pathways was established to bridge scientific exploration with therapeutic innovation. The company emerged as part of a broader trend toward repurposing traditional psychedelic substances for modern psychiatric treatments. Key milestones include the initiation of phase 3 clinical trials for its lead compound, psilocybin (COMP360), aimed at treating depression resistant to conventional therapies.
---
Why Notable
Compass Pathways stands out due to its pivotal role in advancing psychedelic medicine through rigorous scientific and regulatory frameworks. Its work has garnered attention from both the medical community and policymakers, particularly for the breakthrough therapy designation granted by the FDA for psilocybin’s potential in depression treatment. The company’s efforts have sparked global conversations about re-evaluating mental health treatments and the therapeutic benefits of substances traditionally associated with recreational use.
---
In the News
Currently, Compass Pathways remains at the forefront of discussions surrounding psychedelic-assisted therapy, with its phase 3 trials for psilocybin generating significant media coverage. Recent developments include ongoing collaborations with academic institutions and regulatory bodies to refine treatment protocols, underscoring its relevance in shaping future mental health care paradigms.
---
Key Facts
---
